Business
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy regimens, and presented with multiple negative prognostic factors at enrollment (90% of the patients had stage IV disease, most patients had low or undetectable PDL-1 expression, > 90% were current or former smokers, and most patients had failed multiple lines of chemotherapy)mOS of 21.
About this update from Candel Therapeutics, Inc.
[{"type":"image","alt":"Candel Therapeutics","displaySize":"","headline":null,"caption":"Candel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":137,"url":"https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_0g4zgCUCZX.eG19M3SXZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e791e10481877ea34bb2d8e55bba5dfe","width":300,"height":137}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy regimens, and presented with multiple negative prognostic factors at enrollment (90% of the patients had stage IV disease, most patients had low or undetectable PDL-1 expression, > 90% were current or former smokers, and most patients had failed multiple lines of chemotherapy)","length":493,"tagName":"p"}]},{"val":[{"type":"text","content":"mOS of 21.5 months was observed in patients with progressive disease at baseline despite ICI therapy (cohort 2), markedly exceeding mOS which has been reported in published literature for this population with standard of care of docetaxel chemotherapy (mOS of 9.8-11.8 months)","length":276,"tagName":"p"}]},{"val":[{"type":"text","content":"Long tail of survival observed in 37% (15/41) of patients with progressive disease despite ICI treatment at enrollment, who were still alive more than 2 years after CAN-2409 administration at the time of data cutoff (March 3, 2025)","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Evidence of a systemic immune response with regression of both injected and uninjected lesions observed in approximately two-thirds of patients with metastatic disease and at least one uninjected tumor (abscopal effect)","length":219,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1219,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Statistically significant improved overall survival in non-squamous NSCLC compared to squamous NSCLC after experimental treatment with CAN-2409, supported by immunological biomarker data; mOS of 25.4 months in per protocol population o...